<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03585803</url>
  </required_header>
  <id_info>
    <org_study_id>KMRC011-01</org_study_id>
    <nct_id>NCT03585803</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011</brief_title>
  <official_title>A Dose Blocked-Randomized, Single-Blind, Placebo-Controlled and Dose-Escalation Phase I Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011 After Intramuscular Administration in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intron Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intron Biotechnology, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to evaluate the safety, tolerability, pharmacokinetic and&#xD;
      pharmacodynamic of KMRC011 injection in healthy adult volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 11, 2018</start_date>
  <completion_date type="Actual">November 28, 2019</completion_date>
  <primary_completion_date type="Actual">September 11, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with treatment-emergent adverse event or adverse drug reaction</measure>
    <time_frame>Up to 7±1 days after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant changes in hematology test result after injection</measure>
    <time_frame>Up to 7±1 days after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant changes in blood chemistry test result after injection</measure>
    <time_frame>Up to 7±1 days after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant changes in urinalysis test result after injection</measure>
    <time_frame>Up to 7±1 days after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant changes in blood coagulation test result after injection</measure>
    <time_frame>Up to 7±1 days after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant changes in ECG (Electrocardiogram) after injection</measure>
    <time_frame>Up to 7±1 days after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant changes in vital sign after injection</measure>
    <time_frame>Up to 7±1 days after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant physical abnormality after injection</measure>
    <time_frame>Up to 7±1 days after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum concentration (Cmax) of KMRC011</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of the maximum serum concentration (Tmax) of KMRC011</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration versus time curve, from time 0 to the last measurable concentration (AUC0-t) of KMRC011</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration versus time curve from time 0 to infinity (AUCinf) of KMRC011</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of AUCinf due to extrapolation from time of last measurable concentration to infinity (AUCextra) of KMRC011</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance (CL/F) of KMRC011</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vd/F) of KMRC011</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (t1/2) of KMRC011</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum effect over the time span specified (Emax) of G-CSF</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum effect over the time span specified (Emax) of IL-6</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the effect versus time curve, from time 0 to the last measurable concentration (AUEC0-t) of G-CSF</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the effect versus time curve, from time 0 to the last measurable concentration (AUEC0-t) of IL-6</measure>
    <time_frame>Pre-dose(0 hours) and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of KMRC011</measure>
    <time_frame>Until the study completion, approximately up to 35 weeks</time_frame>
    <description>A dose that is one level lower than the dose which Dose Limiting Toxicity (DLT) incidence is 33% or more is determined as a Maximum Tolerated Dose (MTD). If the Dose Limiting Toxicity (DLT) incidence is lower than 33% at all doses level, we conclude Maximum Tolerated Dose (MTD) cannot be determined.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of subjects who expressed Anti-Drug (KMRC011) Antibody (ADA)</measure>
    <time_frame>Up to 28±2 days after injection</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Acute Radiation Syndrome</condition>
  <arm_group>
    <arm_group_label>KMRC011 5μg or Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KMRC011 10μg or Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KMRC011 15μg or Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KMRC011 20μg or Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KMRC011 25μg or Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KMRC011 5μg or Placebo</intervention_name>
    <description>Intramuscular Injection of KMRC011 5μg or Placebo(Normal Saline) 0.1ml</description>
    <arm_group_label>KMRC011 5μg or Placebo</arm_group_label>
    <other_name>Cohort 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KMRC011 10μg or Placebo</intervention_name>
    <description>Intramuscular Injection of KMRC011 10μg or Placebo(Normal Saline) 0.2ml</description>
    <arm_group_label>KMRC011 10μg or Placebo</arm_group_label>
    <other_name>Cohort 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KMRC011 15μg or Placebo</intervention_name>
    <description>Intramuscular Injection of KMRC011 15μg or Placebo(Normal Saline) 0.3ml</description>
    <arm_group_label>KMRC011 15μg or Placebo</arm_group_label>
    <other_name>Cohort 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KMRC011 20μg or Placebo</intervention_name>
    <description>Intramuscular Injection of KMRC011 30μg or Placebo(Normal Saline) 0.4ml</description>
    <arm_group_label>KMRC011 20μg or Placebo</arm_group_label>
    <other_name>Cohort 4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KMRC011 25μg or Placebo</intervention_name>
    <description>Intramuscular Injection of KMRC011 45μg or Placebo(Normal Saline) 0.5ml</description>
    <arm_group_label>KMRC011 25μg or Placebo</arm_group_label>
    <other_name>Cohort 5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A male whose age is between 19 and 55 years of age&#xD;
&#xD;
          -  A person whose body mass index is between 18.5 and 27 kg/m2 at screening&#xD;
&#xD;
          -  A person who has the ability and willingness to participate in the clinical trial&#xD;
&#xD;
          -  A person who voluntarily agrees with the clinical trial after hearing and fully&#xD;
             understanding the detailed explanation of this clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A person who has a clinically significant disease or history of liver, kidney,&#xD;
             neuropsychiatry, immune system, respiratory system, endocrine system,&#xD;
             hematology*oncology system, cardiovascular system, etc.(In the case of liver disease&#xD;
             items, it includes subjects who have hepatitis virus)&#xD;
&#xD;
          -  A person who has clinical history of hypersensitivity reactions to the major&#xD;
             components or constituents of investigational product or other clinically significant&#xD;
             hypersensitivity reactions to drugs or foods, or those with allergic diseases&#xD;
             requiring treatment&#xD;
&#xD;
          -  A person with infectious disease or severe trauma within 21 days of the randomization&#xD;
             date&#xD;
&#xD;
          -  A person whose serum AST, ALT or γ-GT levels exceed 1.5 times the upper limit of the&#xD;
             reference range at screening&#xD;
&#xD;
          -  A person whose QTcF on the electrocardiogram exceeds 430 msec or who has a clinically&#xD;
             significant abnormal rhythm at screening&#xD;
&#xD;
          -  A person with a glomerular filtration rate less than 60 mL/min/1.73 m2 calculated from&#xD;
             serum creatinine at screening&#xD;
&#xD;
          -  A person with a systolic blood pressure less than 100 mmHg, greater than 150 mmHg,&#xD;
             diastolic blood pressure less than 60 mmHg, or greater than 100 mmHg at screening&#xD;
&#xD;
          -  A person with thrombocytopenia or coagulopathy which should not be given intramuscular&#xD;
             injection&#xD;
&#xD;
          -  A person whose weekly average drinking amount exceeds 140g of alcohol per week&#xD;
&#xD;
          -  A person whose daily average smoking amount exceeds 10 per day&#xD;
&#xD;
          -  A person who have received a drug that can significantly affect the absorption,&#xD;
             distribution, metabolism or excretion of the investigational product within 14 days of&#xD;
             the injection&#xD;
&#xD;
          -  A person who has the history of substance abuse or positive urine screening test&#xD;
&#xD;
          -  A person who have received a investigational product or a bioequivalence study drug&#xD;
             within at least 90 days prior to the randomization&#xD;
&#xD;
          -  A person who donated whole blood within 60 days before the randomization, or donated&#xD;
             components of blood within 30 days&#xD;
&#xD;
          -  A person who dose not have a medically approved contraceptive during the trial and has&#xD;
             a plan to provide sperm&#xD;
&#xD;
          -  A person who has clinically significant abnormalities from clinical laboratory test&#xD;
&#xD;
          -  A person who is deemed ineligible for clinical trials by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung-Ryul Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Gangnam-gu</city>
        <state>Seoul</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 3, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiation Injuries</mesh_term>
    <mesh_term>Acute Radiation Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

